Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematopoietic and Lymphatic System Neoplasm: early-phase trial registry
48 of 63 indexed Hematopoietic and Lymphatic System Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #222 of 28,707 conditions by registered trial count.
63 US clinical trials · 48 currently recruiting · #222 of 28,707 conditions by registered trial count
Hematopoietic and Lymphatic System Neoplasm: 63 US clinical trials tracked, 48 recruiting.
Hematopoietic and Lymphatic System Neoplasm is the subject of 63 registered US clinical trials on ClinicalTrials.gov, 48 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 20 of these trials.
Enrollment posture brief
Registry condition hematopoietic-and-lymphatic-system-neoplasm
OPEN 48 | RECR 76% | LATE 4 | EARLY 17 | RANK #222 | SPON 20
Volume-matched condition peers
Nearest open-share peer: TBI (Traumatic Brain Injury) (76% recruiting · 21 trials)
Hematopoietic and Lymphatic System Neoplasm lists 48 open slots (76% of 63 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematopoietic and Lymphatic System Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematopoietic and Lymphatic System Neoplasm is recruiting above its size-band peers.
48 of 63 indexed trials (76.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hematopoietic and Lymphatic System Neoplasm research.
Mayo Clinic accounts for 20 of 63 trials (31.7%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Hematopoietic and Lymphatic System Neoplasm enrolment sits around 60 participants.
Median target enrolment is 60 among the 63 trials that report a genuine target (sentinel values excluded). 36 of those (57.1%) plan for fewer than 100 participants.
-
Hematopoietic and Lymphatic System Neoplasm research is mostly interventional.
46 interventional and 17 observational studies make up this index (73% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
63 total, page 1 of 2
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
Mayo Clinic
NCT06304168
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
National Cancer Institute LAO
NCT02474160
Impact of Physician Behavior on Cancer Distress
Mayo Clinic
NCT07325006
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Mayo Clinic
NCT02958462
A Virtual Community Health Educator for Increasing Clinical Trial Referrals Among Cancer Patients and Their Caregivers
Mayo Clinic
NCT07126496
Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
Mayo Clinic
NCT06353191
A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors (ASCENT)
Mayo Clinic
NCT06198010
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
NRG Oncology
NCT06279013
Web-Based Toolkit to Improve Cancer-Related Emotional Distress and Anxiety in Rural Older Cancer Survivors
Northwestern University
NCT07290543
Genetic Testing for the Prevention of Cancer in Indigenous American Communities (JUNIPER Trial)
Mayo Clinic
NCT06569316
Evaluating a Mobile Health Application Intervention for Caregiver Instruction in Manual Therapy for Chemotherapy-Induced Peripheral Neuropathy
Mayo Clinic
NCT06945380
Pre-Operative Guided Meditation to Reduce Pre-Operative Anxiety in Patients Undergoing Cancer-Directed Surgery
Ohio State University Comprehensive Cancer Center
NCT06949943
Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning
Mayo Clinic
NCT06200116
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
Children's Oncology Group
NCT06410209
Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors
Roswell Park Cancer Institute
NCT06565260
Ambient Sensing Room to Detect Early Signs of Adverse Events in Hospitalized Patients With Cancer
Mayo Clinic
NCT07477886
Distance-Based Exercise to Preserve Function and Prevent Disability
Alliance for Clinical Trials in Oncology
NCT07059884
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
Mayo Clinic
NCT06880861
Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer
OHSU Knight Cancer Institute
NCT06562777
Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy
Mayo Clinic
NCT06723041
CREATE: Art for Children With Cancer
OHSU Knight Cancer Institute
NCT06342453
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
NCT05031897
Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting
City of Hope Medical Center
NCT07126301
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Fred Hutchinson Cancer Center
NCT06817889
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Children's Oncology Group
NCT06513962
Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors
University of Michigan Rogel Cancer Center
NCT06941324
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
National Cancer Institute (NCI)
NCT05691491
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT06013423
Different Types of Massage Therapy to Reduce Anxiety During Chemotherapy Infusion in Patients With Cancer
City of Hope Medical Center
NCT07184294
A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment
University of Michigan Rogel Cancer Center
NCT07365007
L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance
City of Hope Medical Center
NCT07220447
Data-Driven Strategies for Patient Engagement About Cancer Clinical Trials
University of Southern California
NCT07456436
Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers
Wake Forest University Health Sciences
NCT06709404
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
NCT06712810
Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer Survivors
City of Hope Medical Center
NCT06500377
Voices: Messages of Wisdom and Hope in the Face of Illness
Mayo Clinic
NCT07381179
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Yuanquan Yang
NCT06470971
Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial
Fred Hutchinson Cancer Center
NCT07052630
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Mayo Clinic
NCT06271616
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
Masonic Cancer Center, University of Minnesota
NCT06414278
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
NCT07118176
Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies
Fred Hutchinson Cancer Center
NCT04829136
A Mindfulness-Based Stress Reduction Program for Improving Mental Health Outcomes for Underserved Cancer Patients in Minnesota
Mayo Clinic
NCT07291011
Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
Mayo Clinic
NCT06640010
Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation
Roswell Park Cancer Institute
NCT06798701
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
OHSU Knight Cancer Institute
NCT06895473
Virtual Art Therapy Assisted Re-Integration to Improve Biopsychosocial Outcomes in Adolescent and Young Adult Cancer Survivors, AVATARS Trial
Mayo Clinic
NCT07089927
A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
Mayo Clinic
NCT06600659
NCI COVID-19 in Cancer Patients, NCCAPS Study
National Cancer Institute (NCI)
NCT04387656
Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer
Children's Oncology Group
NCT05228275
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 13 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematopoietic and Lymphatic System Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematopoietic and Lymphatic System Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematopoietic and Lymphatic System Neoplasm page
63 registered trials, 48 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 48 Hematopoietic and Lymphatic System Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Hematopoietic and Lymphatic System Neoplasm trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematopoietic and Lymphatic System Neoplasm condition card totals 63 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.